✦ LIBER ✦

P.2.b.020 Safety and tolerability of levomilnacipran SR in major depressive disorder: results from an open-label, 48-week extension study

✍ Scribed by Mago, R.; Forero, G.; Greenberg, W.M.; Gommoll, C.; Chen, C.

Book ID: 123549280
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 58 KB
Volume: 23
Category: Article
ISSN: 0924-977X
DOI: 10.1016/S0924-977X(13)70519-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Tolerability of Levomilnacipr

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

✍ Mago, Rajnish; Forero, Giovanna; Greenberg, William M.; Gommoll, Carl; Chen, Cha 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 288 KB

Erratum to: Safety and Tolerability of L

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

✍ Mago, Rajnish; Forero, Giovanna; Greenberg, William M.; Gommoll, Carl; Chen, Cha 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 137 KB

P.2.c.020 The efficacy and safety of lev

P.2.c.020 The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: results from a phase III clinical trial

✍ A. Bose; C. Chen; C. Gommoll; A. Ruth; J. Terner-Rosenthal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB

P.2.f.021 The safety and tolerability of

P.2.f.021 The safety and tolerability of vortioxetine in treating adults with major depressive disorder after 52 weeks of open-label treatment

✍ Baldwin, D.S.; Mahableshwarkar, A.R.; Chrones, L.; Palo, W.; Matz, J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 59 KB

P.2.c.021 Levomilnacipran in the treatme

P.2.c.021 Levomilnacipran in the treatment of major depressive disorder: an analysis of efficacy and safety data from two phase III studies

✍ W. Greenberg; C. Gommoll; A. Bose; H. Li; A. Ruth 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P01-317 - Safety and tolerability of ari

P01-317 - Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric patients: Results from a 52-week open-label study

✍ W. Landsberg; J.-Y. Loze; G. Lau; G. Manos; R. McQuade; L. Kamen; R. Marcus; R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 French ⚖ 31 KB